Layoffs hit another biotech as Duchenne player Solid Bio cuts staff by 35%

Max Gelman

Senior Editor

Another biotech has joined the ranks of the reorganized, as Duchenne player Solid Biosciences reported a new way of doing things Wednesday and announced layoffs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Layoffs hit another biotech as Duchenne player Solid Bio cuts staff by 35%

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Alcon tried to sink Aurion's IPO in 'Valentine's Day massacre,' new lawsuits say

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

How AI can address ongoing challenges in the life sciences industry

Lay­offs hit an­oth­er biotech as Duchenne play­er Sol­id Bio cuts staff by 35%

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Layoffs hit another biotech as Duchenne player Solid Bio cuts staff by 35%